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Abstract
Background: Persistent organic pollutants (POPs), such as PCBs, DDT and dioxins have in several cross-sectional studies
shown strong associations with type 2 diabetes mellitus. Reversed causality can however not be excluded. The aim of this
case-control study was to evaluate whether POPs concentration is a risk factor for type 2 diabetes.
Methodology/Principal Findings: A case-control study was performed within a well-defined cohort of women, age 50–59
years, from the Southern part of Sweden. Biomarkers for POP exposure, 2,29,4,49,5,59-hexachlorobiphenyl (CB-153) and 1,1-
dichloro-2,2-bis (p-chlorophenyl)-ethylene (p,p9-DDE) were analyzed in stored serum samples, which were collected at the
baseline examination when the cohort was established. For 107 out of the 371 cases, serum samples were stored at least
three years before their type 2 diabetes was diagnosed. In this data set, CB-153 and p,p9-DDE were not associated with an
increased risk to develop type 2 diabetes. However, when only the cases (n=39) that were diagnosed more than six years
after the baseline examination and their controls were studied, the women in the highest exposed quartile showed an
increased risk to develop type 2 diabetes (OR of 1.6 [95% 0.61, 4.0] for CB-153 and 5.5 [95% CI 1.2, 25] for p,p9-DDE).
Conclusions/Significance: The results from the present case-control study, including a follow-up design, confirms that p,p9-
DDE exposure can be a risk factor for type 2 diabetes.
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Introduction
The incidence of type 2 diabetes is rapidly increasing world-
wide [1]. The main factors identified as responsible for the disease
are an aging population with a genetic predisposition for diabetes,
change in lifestyle such as low physical activity, obesity and
smoking. In addition, multiple reports corroborate the association
between persistent organochlorine pollutants (POPs) such as
polychlorinated biphenyls (PCBs), dioxins and dichloro-diphenyl-
trichloroethane (DDT) and type 2 diabetes. Since the 1930s, PCBs
and DDT have been manufactured and released into the
environment. These pollutants are highly lipophilic, hence bio-
accumulate in the food chain and due to their long half lives they
are still detected in humans even though they were banned in most
countries in the 1970s and 1980s [2]. Concentrations of most of
these pollutants have been diminishing in the environment, the
food chain and the human body over recent decades, in most
Western countries. However, there are subgroups in the general
population that still show an elevated body burden due to dietary
habits and current or past exposures. In studies with a cross-
sectional design surprisingly strong associations have been shown
between serum concentrations of POPs and type 2 diabetes
[3–14]. If these associations reflect a true effect of environmental
exposures on the incidence of diabetes, then this is the largest
public health effect observed for POPs so far. However, the
majority of recent studies were cross-sectional and a direct cause
has so far not been shown, thus follow-up studies are
needed.
Altered lipid metabolism [15], altered glucose transport [16,17]
and alterations in the insulin signaling pathway [18] are potential
mechanisms that might be involved in the association between
POPs and diabetes. Diabetes in itself is also known to cause a
dysregulation of fat metabolism, which in turn might influence the
distribution and elimination of POPs. Information from a recent
study of insulin sensitivity and POPs in pregnant women also
shows an association within the non-pathologic range of insulin
sensitivity [19].
A recent commentary by Jones and colleagues stressed the
importance of new clinical, toxicological, and epidemiological
studies, in particular those that integrate several levels of evidence
over a long period [20]. The aim of the present case-control study,
performed within a well-defined cohort of women from the
Southern part of Sweden, was to elucidate to what extent POP
exposure may have contributed to the development of type 2
diabetes. We made the analysis of two biomarkers for POP
exposure, 2,29,4,49,5,59-hexachlorobiphenyl (CB-153) and 1,1-
dichloro-2,2-bis (p-chlorophenyl)-ethylene (p,p9-DDE), in serum
collected before the cases had type 2 diabetes diagnosed.
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Study population and design
Between December 1995 and February 2000 a generic survey based
on a questionnaire, physical examinations, and laboratory assessments
were completed on 6 917 women (corresponding to 64% participating
rate) aged 50–59 years and living in the five municipalities in the Lund
area, located in Southern Sweden (the Women’s Health In the Lund
Area cohort - WHILA). A detailed description of the WHILA cohort
has been given elsewhere [21]. In brief, the women were discriminated
as positive or negative to each one of eight variables linked to the
metabolic syndrome (hyperglucemia, dyslipidemia, obesity and
hypertensive disorders). Women with the metabolic syndrome features
(positive, n=3144) underwent a baseline Oral Glucose Tolerance Test
(OGTT), one to four weeks later. By linkage with the Swedish in-
patient and out-patient registers, women from the WHILA cohort who
had developed type 2 diabetes before 31 December 2006, were
identified. A randomly selected subgroup (n=221) of women without
the metabolic syndrome features, also underwent OGTT, and the
results corroborated the very low prevalence of previously unknown
diabetes among women outside the group. Women with previously
confirmed diabetes (n=139) were excluded from further studies. In
total, 410 women were diagnosed with type 2 diabetes after the
baseline examination. A case-control study was performed within the
WHILA cohort. Blood samples were obtained from all participating
women at the baseline examination and were stored at 270uCu n t i l
the present POP analyses were run. The study was performed in
accordance with the Declaration of Helsinki and approved by the
Research Ethics Committee at Lund University. All participants
accepted with verbal informed consents.
Cases
Out of 410 incident diabetic women (cases) 39 were not eligible
for the current study due to lack of serum samples. Background
characteristics for the remaining 371 cases are presented in
Table 1. Fifty-six percent were diagnosed with type 2 diabetes
within one year after baseline examination.
Controls
For each case, one control was randomly selected from the
WHILA cohort, matched for age, calendar-year, body mass index
(BMI), and according to positive or negative selection criteria for
OGTT at the baseline examination, i.e. presence or not of any
features of the metabolic syndrome.
Biomarkers of exposure
In the present study CB-153 has been used as a biomarker
for PCB exposure. CB-153 correlates very well (r=0.98) with
both total PCB concentrations in plasma and serum from
Swedish subjects [22,23] and with 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD) equivalent (TEQ) in plasma from PCB
(r=0.89). Moreover, the major DDT metabolite p,p9-DDE
which has anti-androgenic effect and is found in relatively high
serum concentrations in adult Swedish people, has also been
used [24].
Table 1. Background characteristics for 371 women from the Southern part of Sweden who were diagnosed for type 2 diabetes
after the baseline investigation (cases) and a corresponding number of matched control women.
Controls (n=371) Cases (n=371)
Variables Median (Min, Max) Median (Min, Max)
Calendar-year at baseline
a 1998 (1995, 2000) 1998 (1995, 2000)
Age at baseline (years)
a 57.6 (50.7, 63.8) 57.3 (51.1, 63.8)
BMI at baseline (kg/m
2)
a 28.5 (18.2, 43.8) 28.3 (17.9, 47.0)
BMI at 25 years of age (kg/m
2) 21.7 (15.8, 33.7) 21.4 (15.4, 34.6)
Time between baseline and T2DM diagnosis (years) 0.23 (0.01, 10.5)
Percent Percent
Family history of T2DM
b 17 18
Born in Sweden 91 91
Education
Compulsory school 29 32
Senior high school 44 45
University 27 23
Smoking history at baseline
Ex smoker 20 22
Current smoker 12 16
Moderate/High alcohol intake
c 91 6
Hormone replacement therapy at baseline 30 34
Low leisure time exercise
d 64 66
Low physical activity at work
e 33 35
aMatching variable.
bFirst-degree relatives.
cMore than 84 gram alcohol per week.
dLess than one hour of strenuous training session per week.
eMostly sedentary work.
doi:10.1371/journal.pone.0007503.t001
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All 742 small (200 ml) serum samples were shipped frozen to the
Laboratory of Chemistry (National Public Health Institute) in
Kuopio in 21
st January 2008, where the levels of two individual
POPs; p,p9-DDE and CB 153 were measured as pg/ml of serum.
The chemical analyses have recently been described in detail [25].
Briefly, each sample of serum, 200 ml, was pipetted to a pre-
cleaned 8 ml glass test tube, and spiked with
13C-labelled p,p9-
DDE and CB-153 internal standards. Ethanol (p.a. purity) was
added to precipitate proteins and equilibrate the internal standards
during the 5 min period in ultrasonic bath. For extraction of
analytes, 2.0 ml of hexane (p.a. purity) was added to sample and
the sample tube was vortexed for 10 min at 2000 rpm with an
automatic shaker. The sample was cleaned up by adding 1.0 ml of
15% sulphuric acid impregnated silica and continuing the vortex
for 5 minutes more. The sample was centrifuged for 2 min in
3500 rpm to form a solid precipitate. The clear hexane fraction on
top was poured into another test tube, evaporated to a small
volume, transferred to autosampler vial, and a recovery standard
(
13C CB-128) was added. The final volume of the sample was
adjusted to 200 ml of toluene.
Laboratory reagent blanks and control serum samples were
pipetted and prepared using test tubes from the same batch as real
samples. No signs of contamination or losses by adsorption were
observed in these quality control samples.
The quantification was performed by high resolution mass
spectrometer (Micromass Ultima, Waters) with electron impact
ionisation and selective ion recording with a resolution of 10 000.
Two most intensive ions of each analyte or internal standard were
monitored. Mass spectrometer was equipped with a HP 6890
(Hewlett Packard) gas chromatograph. A fused silica capillary
column, DB-5 MS (length, 30 m; ID, 0.25 mm; film thickness,
0.25 mm)wasused to separate theanalytes.Two ml was injected into
a split-splitless injector kept at 280uC. The temperature program for
the gas chromatograph was: 140uC (2 min), 20uC/min to 190uC
(0 min), 8uC/min to 260uC (0 min), 40uC/min to 300uC (4 min).
Limits of detection and limits of quantification were 4.3 and
11.5 pg/ml for p,p9-DDE, and 3.1 pg/ml and 8.2 pg/ml for CB-
153, respectively. These were significantly lower than the lowest
measured concentrations in the cohort (63 pg/ml for p,p9-DDE
and 88 pg/ml for CB-153).
The Laboratory of Chemistry is an accredited testing laboratory
(T077). The scope of accreditation covers POPs from serum samples.
Statistical analyses
The association between POP exposure and risk of developing
type 2 diabetes was evaluated by conditional logistic regression
(EGRET), given odds ratios (OR) as the risk measure with 95%
confidence intervals (CI). The exposure variables (CB-153 and
p,p9-DDE) were analyzed as continuous variables as well as
categorized into quartiles and tertiles, respectively, based on the
distributions among all controls. Women with serum concentra-
tions in the highest quartile (or tertile) were considered as exposed.
In addition, separate analyses were performed for the set of cases
and controls where the cases had their type 2 diabetes diagnosed at
least one, three, five and seven years after the base-line
examination, respectively. The correlation between the serum
concentrations of CB-153 and p,p9-DDE was relatively high
(rs=0.66), and we did therefore not include these exposure values
simultaneously in the models.
The similarities between cases and controls regarding age at
primary screening, calendar-year and body mass index, confirm
that the matching was successfully performed (Table 1). We did
analyse our case-control data with conditional logistic regressions
and did accordingly, by definition, adjust for these variables.
Other background characteristics and potential risk factors for
type 2 diabetes, such as heredity, country of birth, education,
smoking history, alcohol intake, hormone replacement therapy,
and physical activity were very similar among cases and controls
(Table 1). None of these latter variables had any strong association
with POP exposure levels and we did therefore not include them
as potential confounders in the models.
Results
The mean concentrations of CB-153 and p,p9-DDE among all
cases were very similar to all controls (Table 2). For the set of cases
and controls where the cases had type 2 diabetes diagnosed at least
seven years after the baseline examination (n=39), the cases had a
22% higher mean concentration of CB-153 (1560 and 1280 pg/
mL) and a 46% higher mean concentration of p,p9-DDE (5680 and
3890 pg/mL) compared with controls.
Table 2. Serum concentrations (pg/mL) of CB-153 and p,p9-DDE among women from the Southern part of Sweden who were
diagnosed with type 2 diabetes after the baseline investigation (cases) and a corresponding number of matched control women.
All ,1 year .3 years .7 years
Controls
(n=371)
Cases
(n=371)
Controls
(n=208)
Cases
(n=208)
Controls
(n=107)
Cases
(n=107)
Controls
(n=39)
Cases
(n=39)
CB-153
Mean (sd) 1470 (740) 1440 (780) 1510 (770) 1480 (840) 1440 (740) 1450 (710) 1280 (730) 1560 (890)
Median (Min, Max) 1340 (88, 6330) 1270 (250, 7280) 1400 (88, 6330) 1260 (250, 7280) 1290 (190, 5134) 1340 (310, 4160) 1100 (190, 3360) 1360 (380, 4160)
Fraction .1790
a 25 25 27 26 22 28 23 33
p,p9-DDE
Mean (sd) 3760 (3550) 4110 (4460) 3770 (3880) 3830 (4120) 3930 (3160) 5140 (5550) 3890 (3770) 5680 (6160)
Median (Min, Max) 2890 (63, 34860) 2890 (160, 39770) 2750 (63, 34860) 2780 (160, 39770) 3050 (500, 17750) 3370 (260, 29190) 2890 (530, 17750) 3610 (280, 29190)
Fraction .4600
a 25 26 24 22 27 35 20 44
Figures are also given for the set of cases and controls were the cases had T2DM diagnosed ,1, .3, or .7 years after the baseline investigation.
aCorresponding to the 75
th percentile among all controls.
doi:10.1371/journal.pone.0007503.t002
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in the highest exposure quartile showed no increased risk to
develop type 2 diabetes as compared to women in the three lower
quartiles, irrespectively if investigating the concentrations for CB-
153 or p,p9-DDE (OR 0.99 and 1.1, respectively, Table 3). The
corresponding ORs increased gradually, i.e. the longer time that
had passed between the baseline examination and the time to
diagnose. If the cases were diagnosed at least seven years after the
baseline examination, OR of 1.6 (95% 0.61, 4.0) for CB-153 and
5.5 (95% CI 1.2, 25) for p,p9-DDE were obtained. The patterns
observed in Table 3 were very much the same if we replaced the
highest quartiles with the highest tertiles as the exposed category
(data not shown). Moreover, when we used continuous exposure
variables, the picture was similar, i.e., the higher effect estimates,
the longer time that had passed between the baseline examination
and the time to diagnose (data not shown).
Discussion
Among women from the general population, the present study
indicate that high serum concentrations of p,p9-DDE is a strong
risk factor for developing type 2 diabetes later in life. A five-fold
statistically significant increased risk was observed among the
individuals with the longest follow-up. This finding is in
accordance with the results from previous cross-sectional studies
[3–9,12,26]. Although less pronounced, similar pattern was
observed for CB-153. Thus, our data support that POP exposure
can be a risk factor for type 2 diabetes.
The present study has some possible limitations. The majority
(56%) of the cases were diagnosed within one year after baseline
examination. At baseline examination some of the women with
hypertensive disorders or dyslipidemia, that required pharamcologi-
cal treatment, were referred to their general practitioner (GP) and
these contacts might have led to increased awareness of the risk to
develop diabetes and therefore the women were diagnosed shortly
after baseline examination. However, the majority of the women with
some metabolic features at baseline examination, were only given life
style consultation regarding exercise, smoking, diet and alcohol use.
We can only speculate, but it is reasonable to believe that after being
aware of how their life style might trigger the risk to develop diabetes,
the women in this group contacted their GPs for a new examination.
This has implications for the statistical power regarding the long term
follow-up of the study. Although the strong associations observed in
our study did reach statistical significance, it has to be confirmed in
larger follow-up studies. Further, in the original WHILA study, 36%
did not participate. Possible differences between participants and
non-participants have previously been thoroughly analyzed [21] and
in the present study we believe that the relatively high fraction of non-
participants in the original cohort study is of minor importance. The
reason for this statement is that women from the general population
are not aware of their body burden of POPs.
Due to the limited amount of serum available from the biobank,
the chemical analyses was restricted to CB-153 and p,p9-DDE and
we had no possibility to lipid adjust our samples. Although there
are no experimental data supporting that di-ortho PCB congeners
such as CB-153, will have a diabetogenic effect by themselves, we
know from other studies that CB-153 serves as a good proxy
biomarker for total PCB as well as for TCDD TEQ [23]. p,p9-
DDE was selected due to its anti-androgenic properties and
because it is still found in relatively high serum concentrations
among adult Swedish people [24]. Regarding the lack of lipid
adjusted exposure measurements, we do not see this as a major
problem due to the very strong correlations (r.0.90) found
between fresh and lipid adjusted samples [22]. Moreover,
concentrations of serum triglycerides, at baseline examination,
did not differ between cases and controls. However, we can not
exclude that other factors created some statistical noise, thereby
biasing the results toward the null hypothesis, which means that
we underestimate the true extent of an effect.
The major strength of the study was the access to stored serum
samples from women participating in the WHILA study, which was
designed for investigating risk factors for developing type 2 diabetes
and therefore includes information on well-known risk factors. The
cohort is well-defined and more than 90% of the women in the
present study were born in Sweden and had Caucasian ethnicity. In
addition, the criteria for type 2 diabetes was well described [27] and
the cases had their diagnosis given after a medical examination and
were not self reported. Another important aspect of the present
study is that for 107 cases the concentrations of CB-153 and p,p9-
DDE were measured at least three years before type 2 diabetes was
diagnosed. This means that the present study is one of very few
studies with a prospective design, and to the best of our knowledge,
has the largest numbers of cases. A very recent prospective study
from the US, with somewhat lower concentrations of p,p9-DDE, did
also show strong associations between p,p9-DDE serum levels and
the risk of developing type 2 diabetes [13]. The study did, however,
only include nine incident female cases.
Levels of PCBs and p,p9-DDE have been declining in the
general population in Sweden over the past decades whereas the
incidence and prevalence of type 2 diabetes has increased quite
dramatically, as for most industrialized countries, during the same
time period [1,28].
Since both p,p9-DDE and CB-153 have a long half life (five to ten
years), we believe that long term exposure, over a period of several
decades, at least in part reflect the concentration present. [29].
Recent studies have shown strong associations between POP
exposure levels in the general population and type 2 diabetes. This
Table 3. Odds ratios (OR) with 95% confidence intervals (CI)
obtained from conditional logistic regressions.
OR 95% CI
CB-153 (pg/mL)
.1790 vs #1790 (ref)
a
All (371 sets
b) 0.99 0.71–1.4
,1year (208 sets
b) 0.91 0.59–1.4
.1year (163 sets
b) 1.1 0.66–1.9
.3 years (107 sets
b) 1.4 0.72–2.6
.5 years (74 sets
b) 1.4 0.67–3.1
.7 years (39 sets
b) 1.6 0.61–4.0
p,p9-DDE (pg/mL)
.4600 vs #4600 (ref)
a
All (371 sets
b) 1.1 0.76–1.5
,1year (208 sets
b) 0.90 0.57–1.4
.1year (163 sets
b) 1.3 0.78–2.2
.3 years (107 sets
b) 1.5 0.80–2.8
.5 years (74 sets
b) 2.5 0.97–6.4
.7 years (39 sets
b) 5.5 1.2–25
Figures are given when all women were included in the analyses, as well as
separately for the set of cases and controls were the cases had type 2 diabetes
diagnosed ,1, .1, .3, .5o r.7 years after the baseline investigation.
aThe cut-off level corresponding to the 75
th percentile among all women.
bn Sets=n cases+n controls.
doi:10.1371/journal.pone.0007503.t003
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POPs present in the environment. There are however some
possible explanations to this circumstance. First, obesity which
undoubtedly is a well known risk factor to type 2 diabetes is
increasing in the western world [30]. In a study by Lee and co-
workers [26] an association between obesity and diabetes became
stronger as serum concentrations of POPs increased. However,
obesity was not associated with diabetes among individuals with
very low concentrations of POPs, in whom the prevalence of
diabetes itself was quite low. This could imply that POPs stored in
adipose tissue may play a role in the current epidemic of type 2
diabetes.
Secondly, endocrine disrupters (EDs) alter normal hormonal
regulation and they may be naturally occurring or environmental
contaminants. Most of the ‘‘old’’ POPs (like PCBs and DDT) and
the ‘‘new’’ such as brominated flame-retardants, polyfluorinated
compounds, and other non-persistent contaminants such as
phthalates and Bispheol A, have endocrine disrupting properties
[31–33]. We do not know whether mixtures of different EDs (the
so-called cocktail effect) are synergistic or additive. The women in
our study were postmenopausal, i.e. with decreasing internal
estrogen levels and to some extent decreasing testosterone levels.
Some women might be more susceptible to these pollutants than
others, and a body burden of POPs, for a long period, might cause
a disruption of hormonal balance and disrupt normal metabolism
of glucose and lipids. Recent reports indicate that EDs have the
potential to stimulate the lipid accumulation in target cells, such as
adipocytes and hepatocytes, related to obesity and metabolic
syndrome, and the accumulation may cause dysfunction in these
cells resulting in induction of the metabolic syndrome [34].
Furthermore, EDs might act by binding to sites that rapidly
activate different signalling cascades which affect the normal
physiology of the endocrine pancreas, altering the regulation of
glucose and lipid metabolism [35].
This taken together makes it reasonable to believe that p,p9-
DDE and CB-153 might trigger development of type 2 diabetes.
A major part of the women in the current study were teenagers
when the exposures to CB-153 and p,p9-DDE were at the highest
levels in Sweden. The most critical exposure window for the risk of
developing type 2 diabetes is not known. One might speculate that
exposure during puberty is of importance. In the present study we
do not know whether the exposure levels measured is correlated
with the levels earlier in life. To clarify this issue, we do
recommend future studies to focus on different exposure windows.
In conclusion, it has been suggested that environmental
pollutants might be a part of the explanation for increased
incidence of type 2 diabetes. Several cross-sectional studies have
indicated strong associations between POP exposure levels and
type 2 diabetes, but the question of reversed causality remained
unanswered. The results from the present case-control study, with
a follow-up design, confirms an association between p,p9-DDE
exposure and type 2 diabetes.
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